Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05040373 · ClinicalTrials.gov registry record
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
A clinical trial of Polyneuropathy and Hereditary Transthyretin-mediated (hATTR) Amyloidosis, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- 10
- Enrollment target
- 7
- Study locations
NCT05040373: Recruiting study of Polyneuropathy and Hereditary Transthyretin-mediated (hATTR) Amyloidosis, sponsored by Alnylam Pharmaceuticals.
NCT05040373 is a study of Polyneuropathy and Hereditary Transthyretin-mediated (hATTR) Amyloidosis that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 10 participants. The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05040373, a study of Polyneuropathy and Hereditary Transthyretin-mediated (hATTR) Amyloidosis, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Primary Outcome
Major congenital malformations will be classified according to the European Concerted Action on Congenital Anomalies and Twins (EUROCAT) and Metropolitan Atlanta Congenital Defects Program (MACDP) classification systems.
Conditions Studied
Study Locations (7)
Other
- Clinical Trial Site - Nantes
- Clinical Trial Site - Münster
- Clinical Trial Site - Pavia
- Clinical Trial Site - Groningen
- Clinical Trial Site - Lisbon
- Clinical Trial Site - Madrid
Iowa
- Clinical Trial Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2030-10-12 |
What NCT05040373 shows while recruiting
NCT05040373 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 2 conditions, with Polyneuropathy appearing as the primary indexed condition, and to 0 interventions.
NCT05040373 lists 7 locations in 2 states (Other, Iowa).
Frequently Asked Questions
What is clinical trial NCT05040373 about?
NCT05040373 is a clinical study titled "Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program". The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
What is the current status of trial NCT05040373?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2020-08-01. Estimated completion is 2030-10-12.
What conditions does trial NCT05040373 study?
This clinical trial studies the following conditions: Polyneuropathy, Hereditary Transthyretin-mediated (hATTR) Amyloidosis.
Who is sponsoring clinical trial NCT05040373?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05040373 being conducted?
This trial has 7 study locations across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI